{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T08:04:49Z","timestamp":1765785889242,"version":"3.48.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,15]]},"DOI":"10.7759\/cureus.99243","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T08:01:31Z","timestamp":1765785691000},"source":"Crossref","is-referenced-by-count":0,"title":["Association Between Pre-hospital Medication Use and Outcomes in Patients Hospitalized for COVID-19 Pneumonia: A Multicenter Observational Study in the Netherlands"],"prefix":"10.7759","author":[{"given":"Letao","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Goris-de Geus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iris","family":"de Leeuw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Floortje","family":"Kanits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaccoline","family":"Zegers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan","family":"van Zadelhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noud","family":"Buenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thijs Clemens David","family":"Rettig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique P. L","family":"Hoir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geerke","family":"Duijzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna Marianne","family":"Geleijnse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Endeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"WHO COVID-19 dashboard. (2025). Accessed. May 16, 2025: https:\/\/data.who.int\/dashboards\/covid19."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08921-5","article-title":"Risk and protective factors for COVID-19 morbidity, severity, and mortality","volume":"64","author":"Zhang JJ","year":"2023","unstructured":"Zhang JJ, Dong X, Liu GH, Gao YD. Risk and protective factors for COVID-19 morbidity, severity, and mortality. Clin Rev Allergy Immunol. 2023, 64:90-107. 10.1007\/s12016-022-08921-5","journal-title":"Clin Rev Allergy Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13128","article-title":"Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships","volume":"21","author":"Popkin BM","year":"2020","unstructured":"Popkin BM, Du S, Green WD, et al.. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. Obes Rev. 2020, 21:e13128. 10.1111\/obr.13128","journal-title":"Obes Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06536-3","article-title":"Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients","volume":"21","author":"Dessie ZG","year":"2021","unstructured":"Dessie ZG, Zewotir T. Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients. BMC Infect Dis. 2021, 21:855. 10.1186\/s12879-021-06536-3","journal-title":"BMC Infect Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.70024","article-title":"Effect of comorbidities on the mortality of patients with COVID-19: a systematic review of reviews and meta-analyses","volume":"35","author":"Ganaza-Domingues KL","year":"2025","unstructured":"Ganaza-Domingues KL, Ramos-Milar\u00e9 \u00c1CF, Lera-Nonose DS, et al.. Effect of comorbidities on the mortality of patients with COVID-19: a systematic review of reviews and meta-analyses. Rev Med Virol. 2025, 35:e70024. 10.1002\/rmv.70024","journal-title":"Rev Med Virol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2020.12.041","article-title":"Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea","volume":"104","author":"Huh K","year":"2021","unstructured":"Huh K, Ji W, Kang M, et al.. Association of prescribed medications with the risk of COVID-19 infection and severity among adults in South Korea. Int J Infect Dis. 2021, 104:7-14. 10.1016\/j.ijid.2020.12.041","journal-title":"Int J Infect Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2020-317336","article-title":"Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis","volume":"106","author":"Flacco ME","year":"2020","unstructured":"Flacco ME, Acuti Martellucci C, Bravi F, et al.. Treatment with ACE inhibitors or ARBs and risk of severe\/lethal COVID-19: a meta-analysis. Heart. 2020, 106:1519-24. 10.1136\/heartjnl-2020-317336","journal-title":"Heart"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/CNQ.0000000000000544","article-title":"The effect of prior use of statins on the severity of COVID-19 disease: a retrospective study","volume":"48","author":"Hasani H","year":"2025","unstructured":"Hasani H, Hamidi F, Ahmadi-Forg F, Panahi P, Tofighi Khelejan F. The effect of prior use of statins on the severity of COVID-19 disease: a retrospective study. Crit Care Nurs Q. 2025, 48:143-50. 10.1097\/CNQ.0000000000000544","journal-title":"Crit Care Nurs Q"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08026-0","article-title":"Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner","volume":"23","author":"Rivera AS","year":"2023","unstructured":"Rivera AS, Al-Heeti O, Petito LC, Feinstein MJ, Achenbach CJ, Williams J, Taiwo B. Association of statin use with outcomes of patients admitted with COVID-19: an analysis of electronic health records using superlearner. BMC Infect Dis. 2023, 23:115. 10.1186\/s12879-023-08026-0","journal-title":"BMC Infect Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.hrtlng.2021.04.010","article-title":"Pre-hospital antiplatelet medication use on COVID-19 disease severity","volume":"50","author":"Pan D","year":"2021","unstructured":"Pan D, Ip A, Zhan S, et al.. Pre-hospital antiplatelet medication use on COVID-19 disease severity. Heart Lung. 2021, 50:618-21. 10.1016\/j.hrtlng.2021.04.010","journal-title":"Heart Lung"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12743","article-title":"No association of low-dose aspirin with severe COVID-19 in France: a cohort of 31.1 million people without cardiovascular disease","volume":"6","author":"Botton J","year":"2022","unstructured":"Botton J, Semenzato L, Dupouy J, Dray-Spira R, Weill A, Saint-Lary O, Zureik M. No association of low-dose aspirin with severe COVID-19 in France: a cohort of 31.1 million people without cardiovascular disease. Res Pract Thromb Haemost. 2022, 6:e12743. 10.1002\/rth2.12743","journal-title":"Res Pract Thromb Haemost"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2022.11.027","article-title":"Aspirin and P2Y12 inhibitors in treating COVID-19","volume":"110","author":"Khalaji A","year":"2023","unstructured":"Khalaji A, Behnoush AH, Peiman S. Aspirin and P2Y12 inhibitors in treating COVID-19. Eur J Intern Med. 2023, 110:101-3. 10.1016\/j.ejim.2022.11.027","journal-title":"Eur J Intern Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkad040","article-title":"Comment on 'The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic'. Aspirin therapy in COVID-19: too soon to dismiss its benefits?","volume":"78","author":"Kow CS","year":"2023","unstructured":"Kow CS, Ramachandram DS, Hasan SS. Comment on 'The dangers of non-randomized, observational studies. Experience from the COVID-19 epidemic'. Aspirin therapy in COVID-19: too soon to dismiss its benefits?. J Antimicrob Chemother. 2023, 78:1134-5. 10.1093\/jac\/dkad040","journal-title":"J Antimicrob Chemother"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-023-01309-7","article-title":"Ibuprofen, other NSAIDs and COVID-19: a narrative review","volume":"31","author":"Laughey W","year":"2023","unstructured":"Laughey W, Lodhi I, Pennick G, Smart L, Sanni O, Sandhu S, Charlesworth B. Ibuprofen, other NSAIDs and COVID-19: a narrative review. Inflammopharmacology. 2023, 31:2147-59. 10.1007\/s10787-023-01309-7","journal-title":"Inflammopharmacology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.935280","article-title":"Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19","volume":"12","author":"Zhang J","year":"2022","unstructured":"Zhang J, Sheng H, Tang X, et al.. Non-steroidal anti-inflammatory drugs and clinical outcomes in patients with COVID-19. Front Cell Infect Microbiol. 2022, 12:935280. 10.3389\/fcimb.2022.935280","journal-title":"Front Cell Infect Microbiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2024.107155","article-title":"Vaccinations, cardiovascular drugs, hospitalization, and mortality in COVID-19 and Long COVID","volume":"146","author":"Dashtban A","year":"2024","unstructured":"Dashtban A, Mizani MA, Pasea L, et al.. Vaccinations, cardiovascular drugs, hospitalization, and mortality in COVID-19 and Long COVID. Int J Infect Dis. 2024, 146:107155. 10.1016\/j.ijid.2024.107155","journal-title":"Int J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-021-01939-3","article-title":"Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities","volume":"111","author":"Rieder M","year":"2022","unstructured":"Rieder M, Gauchel N, Kaier K, et al.. Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. Clin Res Cardiol. 2022, 111:322-32. 10.1007\/s00392-021-01939-3","journal-title":"Clin Res Cardiol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2022.11.051","article-title":"Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - a retrospective cohort study on 5392 patients from a tertiary centre","volume":"372","author":"Bistrovic P","year":"2023","unstructured":"Bistrovic P, Sabljic A, Kovacevic I, et al.. Risks associated with prior oral anticoagulation use in hospitalized COVID-19 patients - a retrospective cohort study on 5392 patients from a tertiary centre. Int J Cardiol. 2023, 372:144-9. 10.1016\/j.ijcard.2022.11.051","journal-title":"Int J Cardiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-98778-z","article-title":"Comparison of the impact of chronic corticosteroid therapy on critical care outcomes of COVID-19 patients with and without history of chronic liver disease","volume":"11","author":"Liaquat H","year":"2021","unstructured":"Liaquat H, Shupp B, Rollins S, Schneider Y, Matin A. Comparison of the impact of chronic corticosteroid therapy on critical care outcomes of COVID-19 patients with and without history of chronic liver disease. Sci Rep. 2021, 11:19245. 10.1038\/s41598-021-98778-z","journal-title":"Sci Rep"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2023.08.024","article-title":"Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders","volume":"114","author":"Cheng WJ","year":"2023","unstructured":"Cheng WJ, Shih HM, Su KP, Hsueh PR. Risk factors for poor COVID-19 outcomes in patients with psychiatric disorders. Brain Behav Immun. 2023, 114:255-61. 10.1016\/j.bbi.2023.08.024","journal-title":"Brain Behav Immun"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15525","article-title":"People exposed to proton-pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nationwide matched cohort study","volume":"89","author":"Kodvanj I","year":"2023","unstructured":"Kodvanj I, Homolak J, Trkulja V. People exposed to proton-pump inhibitors shortly preceding COVID-19 diagnosis are not at an increased risk of subsequent hospitalizations and mortality: a nationwide matched cohort study. Br J Clin Pharmacol. 2023, 89:787-831. 10.1111\/bcp.15525","journal-title":"Br J Clin Pharmacol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09639-2","article-title":"Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus","volume":"12","author":"Ma Z","year":"2022","unstructured":"Ma Z, Patel N, Vemparala P, Krishnamurthy M. Metformin is associated with favorable outcomes in patients with COVID-19 and type 2 diabetes mellitus. Sci Rep. 2022, 12:5553. 10.1038\/s41598-022-09639-2","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-023-01472-8","article-title":"Protective effects of home T2DM treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors against intensive care unit admission and mortality in the acute phase of the COVID-19 pandemic: a retrospective observational study in Italy","volume":"14","author":"Monda VM","year":"2023","unstructured":"Monda VM, Voci C, Strollo F, et al.. Protective effects of home T2DM treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors against intensive care unit admission and mortality in the acute phase of the COVID-19 pandemic: a retrospective observational study in Italy. Diabetes Ther. 2023, 14:2127-42. 10.1007\/s13300-023-01472-8","journal-title":"Diabetes Ther"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-021-02507-2","article-title":"Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19","volume":"53","author":"Corrochano M","year":"2022","unstructured":"Corrochano M, Acosta-Isaac R, Mojal S, et al.. Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19. J Thromb Thrombolysis. 2022, 53:96-102. 10.1007\/s11239-021-02507-2","journal-title":"J Thromb Thrombolysis"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14467","article-title":"The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19","volume":"75","author":"Aslan B","year":"2021","unstructured":"Aslan B, Aky\u00fcz A, I\u015f\u0131k F, et al.. The effect of chronic DOAC treatment on clinical outcomes of hospitalized patients with COVID-19. Int J Clin Pract. 2021, 75:e14467. 10.1111\/ijcp.14467","journal-title":"Int J Clin Pract"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13205","article-title":"Direct oral anticoagulant use and risk of severe COVID-19","volume":"289","author":"Flam B","year":"2021","unstructured":"Flam B, Wintzell V, Ludvigsson JF, M\u00e5rtensson J, Pasternak B. Direct oral anticoagulant use and risk of severe COVID-19. J Intern Med. 2021, 289:411-19. 10.1111\/joim.13205","journal-title":"J Intern Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/medicina58111649","article-title":"Analysis of prior aspirin treatment on in-hospital outcome of geriatric COVID-19 infected patients","volume":"58","author":"Zekri-Nechar K","year":"2022","unstructured":"Zekri-Nechar K, Barber\u00e1n J, Zamorano-Le\u00f3n JJ, et al.. Analysis of prior aspirin treatment on in-hospital outcome of geriatric COVID-19 infected patients. Medicina (Kaunas). 2022, 58:1649. 10.3390\/medicina58111649","journal-title":"Medicina (Kaunas)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16968","article-title":"COVID-19 mortality in patients on anticoagulants and antiplatelet agents","volume":"190","author":"Sivaloganathan H","year":"2020","unstructured":"Sivaloganathan H, Ladikou EE, Chevassut T. COVID-19 mortality in patients on anticoagulants and antiplatelet agents. Br J Haematol. 2020, 190:e192-5. 10.1111\/bjh.16968","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-023-03432-3","article-title":"Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI\u2011COVID\u201119 Registry","volume":"18","author":"Dalbeni A","year":"2023","unstructured":"Dalbeni A, Susca N, Daidone M, et al.. Low dose aspirin and clinical outcomes in patients with SARS-CoV-2 pneumonia: a propensity score-matched cohort analysis from the National SIMI\u2011COVID\u201119 Registry. Intern Emerg Med. 2023, 18:2311-19. 10.1007\/s11739-023-03432-3","journal-title":"Intern Emerg Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034040","article-title":"Effect of combination of prophylactic or therapeutic anticoagulation with aspirin on the outcomes of hospitalized COVID-19 patients: an observational retrospective study","volume":"102","author":"Mina J","year":"2023","unstructured":"Mina J, Fleifel M, Haykal T, et al.. Effect of combination of prophylactic or therapeutic anticoagulation with aspirin on the outcomes of hospitalized COVID-19 patients: an observational retrospective study. Medicine (Baltimore). 2023, 102:e34040. 10.1097\/MD.0000000000034040","journal-title":"Medicine (Baltimore)"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2021.05.016","article-title":"Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: a systematic review and meta-analysis of adjusted effect estimates","volume":"108","author":"Martha JW","year":"2021","unstructured":"Martha JW, Pranata R, Lim MA, Wibowo A, Akbar MR. Active prescription of low-dose aspirin during or prior to hospitalization and mortality in COVID-19: a systematic review and meta-analysis of adjusted effect estimates. Int J Infect Dis. 2021, 108:6-12. 10.1016\/j.ijid.2021.05.016","journal-title":"Int J Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0295366","article-title":"The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: a systematic review and meta-analysis","volume":"19","author":"Chen CH","year":"2024","unstructured":"Chen CH, Wang CY, Chen CY, et al.. The influence of prior use of inhaled corticosteroids on COVID-19 outcomes: a systematic review and meta-analysis. PLoS One. 2024, 19:e0295366. 10.1371\/journal.pone.0295366","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1061307","article-title":"Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: evidence from big data","volume":"11","author":"Malekpour MR","year":"2023","unstructured":"Malekpour MR, Abbasi-Kangevari M, Shojaee A, et al.. Effect of the chronic medication use on outcome measures of hospitalized COVID-19 patients: evidence from big data. Front Public Health. 2023, 11:1061307. 10.3389\/fpubh.2023.1061307","journal-title":"Front Public Health"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2021-001925","article-title":"Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study","volume":"7","author":"\u00c1lvaro Gracia JM","year":"2021","unstructured":"\u00c1lvaro Gracia JM, Sanchez-Piedra C, Manero J, et al.. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: results from the COVIDSER study. RMD Open. 2021, 7:e001925. 10.1136\/rmdopen-2021-001925","journal-title":"RMD Open"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2022.1607","article-title":"Mortality and severity of coronavirus disease 2019 in patients with long-term glucocorticoid therapy: a Korean nationwide cohort study","volume":"38","author":"Ku EJ","year":"2023","unstructured":"Ku EJ, Song K, Kim KM, Seo GH, Yoo SJ. Mortality and severity of coronavirus disease 2019 in patients with long-term glucocorticoid therapy: a Korean nationwide cohort study. Endocrinol Metab (Seoul). 2023, 38:253-9. 10.3803\/EnM.2022.1607","journal-title":"Endocrinol Metab (Seoul)"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-080640","article-title":"Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort","volume":"14","author":"Einarsdottir MJ","year":"2024","unstructured":"Einarsdottir MJ, Kibiwott Kirui B, Li H, Olsson D, Johannsson G, Nyberg F, Ragnarsson O. Impact of chronic oral glucocorticoid treatment on mortality in patients with COVID-19: analysis of a population-based cohort. BMJ Open. 2024, 14:e080640. 10.1136\/bmjopen-2023-080640","journal-title":"BMJ Open"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00769-2021","article-title":"The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection","volume":"59","author":"Ward D","year":"2022","unstructured":"Ward D, G\u00f8rtz S, Thomson Ernst M, et al.. The effect of immunosuppressants on the prognosis of SARS-CoV-2 infection. Eur Respir J. 2022, 59:2100769. 10.1183\/13993003.00769-2021","journal-title":"Eur Respir J"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1224737","article-title":"Association of antihypertensive drugs with COVID-19 outcomes: a drug-target Mendelian randomization study","volume":"14","author":"Zhang K","year":"2023","unstructured":"Zhang K, Gao H, Chen M. Association of antihypertensive drugs with COVID-19 outcomes: a drug-target Mendelian randomization study. Front Pharmacol. 2023, 14:1224737. 10.3389\/fphar.2023.1224737","journal-title":"Front Pharmacol"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14751","article-title":"No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study","volume":"87","author":"Sablerolles RS","year":"2021","unstructured":"Sablerolles RS, Hogenhuis FE, Lafeber M, et al.. No association between use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers prior to hospital admission and clinical course of COVID-19 in the COvid MEdicaTion (COMET) study. Br J Clin Pharmacol. 2021, 87:3301-9. 10.1111\/bcp.14751","journal-title":"Br J Clin Pharmacol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000001319","article-title":"Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and the risk of SARS-CoV-2 infection or hospitalization with COVID-19 disease: a systematic review and meta-analysis","volume":"29","author":"Tleyjeh IM","year":"2020","unstructured":"Tleyjeh IM, Bin Abdulhak AA, Tlayjeh H, et al.. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and the risk of SARS-CoV-2 infection or hospitalization with COVID-19 disease: a systematic review and meta-analysis. Am J Ther. 2020, 29:e74-84. 10.1097\/MJT.0000000000001319","journal-title":"Am J Ther"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2020.10.015","article-title":"Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis","volume":"77","author":"Ren L","year":"2021","unstructured":"Ren L, Yu S, Xu W, Overton JL, Chiamvimonvat N, Thai PN. Lack of association of antihypertensive drugs with the risk and severity of COVID-19: a meta-analysis. J Cardiol. 2021, 77:482-91. 10.1016\/j.jjcc.2020.10.015","journal-title":"J Cardiol"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00994-5","article-title":"Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients","volume":"43","author":"Trifir\u00f2 G","year":"2020","unstructured":"Trifir\u00f2 G, Massari M, Da Cas R, et al.. Renin-angiotensin-aldosterone system inhibitors and risk of death in patients hospitalised with COVID-19: a retrospective Italian cohort study of 43,000 patients. Drug Saf. 2020, 43:1297-308. 10.1007\/s40264-020-00994-5","journal-title":"Drug Saf"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02565-1","article-title":"Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study","volume":"22","author":"Sato K","year":"2022","unstructured":"Sato K, White N, Fanning JP, et al.. Impact of renin-angiotensin-aldosterone system inhibition on mortality in critically ill COVID-19 patients with pre-existing hypertension: a prospective cohort study. BMC Cardiovasc Disord. 2022, 22:123. 10.1186\/s12872-022-02565-1","journal-title":"BMC Cardiovasc Disord"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000003059","article-title":"Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients","volume":"40","author":"Gori M","year":"2022","unstructured":"Gori M, Berzuini C, D'Elia E, et al.. Antecedent use of renin-angiotensin system inhibitors is associated with reduced mortality in elderly hypertensive Covid-19 patients. J Hypertens. 2022, 40:666-74. 10.1097\/HJH.0000000000003059","journal-title":"J Hypertens"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11226865","article-title":"COVID-19 infection in rheumatic patients on chronic antimalarial drugs: a systematic review and meta-analysis","volume":"11","author":"Landsteiner de Sampaio Am\u00eandola I","year":"2022","unstructured":"Landsteiner de Sampaio Am\u00eandola I, Aires Pinheiro J, P\u00f3voa P, C\u00e9s de Souza Dantas V, Serafim RB. COVID-19 infection in rheumatic patients on chronic antimalarial drugs: a systematic review and meta-analysis. J Clin Med. 2022, 11:6865. 10.3390\/jcm11226865","journal-title":"J Clin Med"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22446-z","article-title":"Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials","volume":"12","author":"Axfors C","year":"2021","unstructured":"Axfors C, Schmitt AM, Janiaud P, et al.. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021, 12:2349. 10.1038\/s41467-021-22446-z","journal-title":"Nat Commun"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.5812\/aapm.115827","article-title":"An umbrella review of clinical efficacy and adverse cardiac events associated with hydroxychloroquine or chloroquine with or without azithromycin in patients with COVID-19","volume":"11","author":"Shahsavarinia K","year":"2021","unstructured":"Shahsavarinia K, Ghojazadeh M, Ghabousian A, Hatefnia F, Soleimanpour M, Soleimanpour H. An umbrella review of clinical efficacy and adverse cardiac events associated with hydroxychloroquine or chloroquine with or without azithromycin in patients with COVID-19. Anesth Pain Med. 2021, 11:e115827. 10.5812\/aapm.115827","journal-title":"Anesth Pain Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219498","article-title":"Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"80","author":"Strangfeld A","year":"2021","unstructured":"Strangfeld A, Sch\u00e4fer M, Gianfrancesco MA, et al.. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021, 80:930-42. 10.1136\/annrheumdis-2020-219498","journal-title":"Ann Rheum Dis"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.11620","article-title":"Effect of immunosuppressive or immunomodulatory agents on severe COVID-19 outcomes: a population-based cohort study","volume":"5","author":"Marozoff S","year":"2023","unstructured":"Marozoff S, Tan J, Lu N, et al.. Effect of immunosuppressive or immunomodulatory agents on severe COVID-19 outcomes: a population-based cohort study. ACR Open Rheumatol. 2023, 5:685-93. 10.1002\/acr2.11620","journal-title":"ACR Open Rheumatol"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.005","article-title":"Reply to: \"age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients\"","volume":"75","author":"Rodr\u00edguez-Per\u00e1lvarez M","year":"2021","unstructured":"Rodr\u00edguez-Per\u00e1lvarez M, Colmenero J, Salcedo M. Reply to: \"age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients\". J Hepatol. 2021, 75:228-9. 10.1016\/j.jhep.2021.04.005","journal-title":"J Hepatol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-021-07152-2","article-title":"Prior immunosuppressive therapy and severe illness among patients diagnosed with SARS-CoV-2: a community-based study","volume":"36","author":"Velayos FS","year":"2021","unstructured":"Velayos FS, Dusendang JR, Schmittdiel JA. Prior immunosuppressive therapy and severe illness among patients diagnosed with SARS-CoV-2: a community-based study. J Gen Intern Med. 2021, 36:3794-801. 10.1007\/s11606-021-07152-2","journal-title":"J Gen Intern Med"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jjcc.2021.12.012","article-title":"The association of statins use with survival of patients with COVID-19","volume":"79","author":"Kuno T","year":"2022","unstructured":"Kuno T, So M, Iwagami M, Takahashi M, Egorova NN. The association of statins use with survival of patients with COVID-19. J Cardiol. 2022, 79:494-500. 10.1016\/j.jjcc.2021.12.012","journal-title":"J Cardiol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2021.03.002","article-title":"Association between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matching","volume":"15","author":"Lohia P","year":"2021","unstructured":"Lohia P, Kapur S, Benjaram S, Mir T. Association between antecedent statin use and severe disease outcomes in COVID-19: a retrospective study with propensity score matching. J Clin Lipidol. 2021, 15:451-9. 10.1016\/j.jacl.2021.03.002","journal-title":"J Clin Lipidol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2021.03.001","article-title":"Association of pre-admission statin use with reduced in-hospital mortality in COVID-19","volume":"361","author":"Chacko SR","year":"2021","unstructured":"Chacko SR, DeJoy R 3rd, Lo KB, et al.. Association of pre-admission statin use with reduced in-hospital mortality in COVID-19. Am J Med Sci. 2021, 361:725-30. 10.1016\/j.amjms.2021.03.001","journal-title":"Am J Med Sci"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254635","article-title":"Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry","volume":"16","author":"Daniels LB","year":"2021","unstructured":"Daniels LB, Ren J, Kumar K, et al.. Relation of prior statin and anti-hypertensive use to severity of disease among patients hospitalized with COVID-19: findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry. PLoS One. 2021, 16:e0254635. 10.1371\/journal.pone.0254635","journal-title":"PLoS One"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1038\/s41533-022-00300-z","article-title":"The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19","volume":"32","author":"Kushner P","year":"2022","unstructured":"Kushner P, McCarberg BH, Grange L, et al.. The use of non-steroidal anti-inflammatory drugs (NSAIDs) in COVID-19. NPJ Prim Care Respir Med. 2022, 32:35. 10.1038\/s41533-022-00300-z","journal-title":"NPJ Prim Care Respir Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1163\/15718093-BJA10028","article-title":"View. The Dutch Critical Care Triage Guideline on Covid-19: not necessarily discriminatory","volume":"27","author":"den Exter A","year":"2020","unstructured":"den Exter A. View. The Dutch Critical Care Triage Guideline on Covid-19: not necessarily discriminatory. Eur J Health Law. 2020, 27:495-8. 10.1163\/15718093-BJA10028","journal-title":"Eur J Health Law"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424131-association-between-pre-hospital-medication-use-and-outcomes-in-patients-hospitalized-for-covid-19-pneumonia-a-multicenter-observational-study-in-the-netherlands","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T08:01:33Z","timestamp":1765785693000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424131-association-between-pre-hospital-medication-use-and-outcomes-in-patients-hospitalized-for-covid-19-pneumonia-a-multicenter-observational-study-in-the-netherlands"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":57,"URL":"https:\/\/doi.org\/10.7759\/cureus.99243","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,15]]}}}